Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases

Table 1 Summary of the obtained results for CJD and non-CJD cases

Cases		n	Male/Female	Disease duration [months]	Age at death [years]	PAR-2 [ng/ml]	T-tau [pg/ml]	P-tau [pg/ml]	Aβ [pg/ml]	14-3-3
Cases		n	Male/Female	Disease duration [months]	Age at death [years]	PAR-2 [ng/ml]	T-tau [pg/ml]	P-tau [pg/ml]	Aβ [pg/ml]	P	W	N
CJD		36	12/24	6.8 ± 8.3 [1–48]	63.1 ± 8.3 [39–81]	8.78 ± 6.40 [1.25–28.49]	1111.47 ± 264.48 [195–1201]	52.69 ± 30.86 [16–166]	619.39 ± 297.34 [212–1407]	21	7	8
non-CJD		23	15/8	24.1 ± 22.2 [2–84]	71.0 ± 10.4 [53–90]	9.31 ± 8.71 [1.22–41]	632.43 ± 434.03 [65–1201]	47.48 ± 28.38 [15–103]	561.22 ± 421.20 [94–1672]	4	3	16
	AD	6	4/2	28.67 ± 29.87 [2–84]	70 ± 10.66 [54–82]	13.26 ± 14.62 [1.22–41]	926.83 ± 366.99 [268–1201]	53.83 ± 27.67 [29–102]	401 ± 409.04 [94–1109]	1	2	3
	FTLD-TDP	11	7/4	17.2 ± 14.86 [3–46]	70.8 ± 11.4 [53–90]	8.15 ± 5.96 [1.73–21.79]	558.27 ± 424.44 [134–1201]	39.10 ± 24.35 [15–94]	517.64 ± 241.35 [265–1065]	2	0	9
	VD	4	3/1	27.5 ± 31 [2–72]	70.5 ± 7.1 [62–79]	5.03 ± 1.61 [2.79–6.44]	547 ± 521.99 [65–1201]	52.25 ± 38.45 [20–103]	945 ± 755.50 [186–1672]	1	1	2
	PSP	2	1/1	38 ± 2.83 [36–40]	76.5 ± 17.68 [64–89]	12.36 ± 6.05 [8.08–16.64]	328 ± 239 [159–497]	65 ± 42.43 [35–95]	514 ± 55.15 [475–553]	0	0	2

Results are shown as mean ± S.D. [min–max]; P – positive, W – weakly positive, N – negative. AD – Alzheimer’s disease; FTLD-TDP – frontotemporal lobar degeneration with TDP-43 inclusions; PSP – progressive supranuclear palsy; VD – vascular dementia.

ISSN: 1471-2377